

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Francis LEE et al.
Title: METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS
Appl. No.: 10/027,186
Filing Date: 20 December 2001
Patent. No.: 7,037,906 B1
Issue Date: 2 May 2006
Examiner: Shengun WANG
Art Unit: 1614
Confirmation No.: 9673

REQUEST FOR RECONSIDERATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This communication is responsive to the denial of Applicant's Request for Certificate of Correction. The Communication dated 20 August 2008 states "further consideration will be given to your request in this matter upon receipt of a copy of the postcard receipt and 1449 or 892 with the requested reference(s) which were considered by the Examiner."

Enclosed please find a copy of the Information Disclosure Statement, filed 12 June 2002, without the accompanying references, including:

- Transmittal Letter (1 page);
- Information Disclosure Statement (2 pages); and
- Modified Form 1449/PTO (4 pages)

Also enclosed is a copy of the post card receipt dated 12 June 2002 by the OIPE, acknowledging receipt of the Information Disclosure Statement, Form 1449 and Cited References.

In view of these enclosures, Application renews its request for a Certificate of Correction listing the references submitted in Information Disclosure Statement of 12 June 2002.

Applicants request a Certificate of Correction to correct an error in this issued patent. The issued patent issued with only the references- cited by the Examiner on the face of the patent. References cited by Applicants and considered by the Examiner are not on the face of the patent but rather the face of the patent says, "See application file for complete search history."

In view of the change in the attorney representing Applicant, enclosed are new Certificates of Correction (Form PTO/SB/44) reflecting the new correspondence address. Otherwise, the request for Certificate of Correction is identical to that previously presented for consideration.

In accordance with 35 U.S.C. § 254, as this error was the result of a Patent and Trademark Office mistake, no fees are believed due in connection with this Request.

The Office is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the consideration of the present request.

The Commissioner is hereby authorized to charge any fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, to Deposit Account No. 50-4279. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-4279.

Respectfully submitted,

Date 25 February 2009

By /Karen E. Flick/

Customer Number: 75605
Telephone: (650) 284-5575
Facsimile: (650) 284-5596

Karen E. Flick
Attorney for Applicant
Registration No. 44,111

}

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Lee, et al.
SERIAL NUMBER: 10/027,186 EXAMINER: Not Yet Assigned
FILING DATE: December 20, 2001 ART UNIT: 1614
FOR: Methods for Modulating Tumor Growth and Metastasis

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed modified Form PTO-1449 to evidence that the cited information has been fully considered by the United States Patent & Trademark Office during the examination of this application.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

3

The Commissioner is hereby authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 (Reference No. 18217-505).

Respectfully submitted,



Ivor R. Elrja, Reg. No. 39,529
Barry J. Marchberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: June 12, 2002

TRA 1678305v1

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/027,186
	Filing Date	12/20/2001
	First Named Inventor	Lee
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	18217-505

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,940,726	07/10/90	Pettit, et al.			
	A2	4,996,237	02/26/91	Pettit, et al.			
	A3	5,409,953	04/25/95	Pettit, et al.			
	A4	5,561,122	10/01/96	Pettit			
	A5	5,569,786	10/29/96	Pettit, et al.			
	A6	5,661,143	08/26/97	D'Amato, et al.			
	A7	6,342,219	01/29/02	Thorpe, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	99/35150	Arizona Board of Regents	07/15/1999		
	B2	WO	00/48590	Angiogene Pharmaceuticals Ltd.	08/24/2000		
	B3	WO	00/48591	Angiogene Pharmaceuticals Ltd.	08/24/2000		
	B4	WO	94/05682	Pelizzoni	03/17/1994		
	B5	WO	01/74368	Angiogene Pharmaceuticals Ltd.	10/11/2002		
	B6	WO	02/09700	Cancer Research Ventures Ltd.	02/07/2002		
	B7	WO	02/34244	Aventis Pharma	05/02/2002		
	B8	EP	1 068 870	Ajinomoto Co. Inc.	01/17/2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Pettit and Rhodes (1998). "Antineoplastic Agents 389. New Syntheses of the combretastatin A-4 prodrug" <i>Anti-Cancer Drug Design</i> 13: 183-191.
	C2	Petit, et al. (1995). "Antineoplastic Agents 291. Isolation and Synthesis of Combretastatins A-4, A-5 and A-61a" <i>J. Med. Chem.</i> 38: 1666-1672.
	C3	Crombie, et al. (1979). "Isolation of Cannabispiradienone and Cannabidihydrophenantherene. Biosynthetic Relationships Between the spirans and dihydrostilbenes of Thailand Cannabis" <i>Tetrahedron Letts.</i> 7: 661-664.
	C4	Majumder and Joardar. (1984). "Structure of Erianin, a New Bibenzyl Derivative from the Orchid <i>Eria carinata</i> " <i>Indian J. Chem.</i> 23B: 1040-1042.
	C5	Fürstner and Nikolakis (1996). "Ethynylation of Aryl Halides by a Modified Suzuki Reaction: Application to the Synthesis of Combretastatin A-4, A-5 and Lunularic Acid" <i>Liebigs Ann.</i> Pgs. 2107-2113.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C6	Remick, et al. (2000). "A Phase I Pharmacokinetic (PK) Study of Single Dose Intravenous (IV) Combretastatin A4 Prodrug (CA4P) in Patients (PTS) With Advanced Cancer" ASCO Presentation. New Orleans May 23 2000
	C7	Stevenson, et al. (2000). "Phase I/Pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x5 schedule every 21 days" ACCR San Francisco, CA .
	C8	Rustin, et al. (1999). "Combretastatin A4 phosphate (CA4P) selectively targets vasculature in animal and human tumors." <i>Proceedings of the 1999 AACR-NCI-EORT International Conference</i> . Mount Vernon Hospital, Northwood Middlesex UK. Abstract 14.
	C9	Galbraith, et al. (1999). "Quantitative analysis of endothelial cell shape change after treatment with combretastatin A4 phosphate." <i>AACR-NCI-EORTC International Conference</i> . Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Northwood, UK. Abstract 399.
	C10	J. Randal, et al. (2000). "Antiangiogenesis Drugs Target Specific Cancers, Mechanisms." <i>J. National Cancer Institute</i> 92(7): 520-522.
	C11	OXIGENE Announces Promising Clinical Results for Lead Tumor Vascular Targeting Agent, Combretastatin A4 Prodrug. Press Release.
	C12	OXIGENE Signs Letter of Intent with Bristol-Myers Squibb for the Development and Commercialization of Combretastatin. Press Release (22 November 1999). pages 1-2.
	C13	Bristol-Myers Squibb/Oxigene HEALTH-NEWS-Daily (23 November 1999). Press Release.
	C14	OXIGENE announces favorable phase I results for angiogenesis inhibitor. Reuters Medical News. (7 October 1999). Press Release.
	C15	OXIGENE acquires rights to combretastatin. Reuters Medical News. (13 August 1999). Press Release
	C16	Bristol-Myers Squibb and OXIGENE Announce Research and Licensing Agreement for Anti-Tumor Agents. Press Release. Princeton New Jersey (16 December 1999) pgs.1-3.
	C17	Eikesdal, et al. (2000). "The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma." <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 46(3): 645-652. ABSTRACT
	C18	Chaplin, et al. (1999). "Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate." <i>Anticancer Research</i> 19(1A): 189-95. ABSTRACT
	C19	Grosios, et al. (1999). "In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug." <i>British Journal of Cancer.</i> 81(8): 1318-27. ABSTRACT
	C20	Hori, et al. (1999). "Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700." <i>Japanese Journal of Cancer Research</i> 90(9): 1026-38. ABSTRACT.
	C21	Korbelik, et al. (1999). "Examples of adjuvant treatment enhancing the antitumor effect of photodynamic therapy." <i>Proc. SPIE-Int. Soc. Opt. Eng.</i> 3592: 65-72. ABSTRACT.
	C22	Nihei, et al. (1999). "A novel combretastatin A-4 derivative , AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors." <i>Japanese Journal of Cancer Research.</i> 90(9): 1016-25. ABSTRACT.
	C23	Nihei, et al. (1999). "Evaluation of antivascular and antimetabolic effects of tubulin binding agents in solid tumor therapy." <i>Jpn. J. Cancer Res.</i> 90(12): 1387-1386. ABSTRACT.
	C24	Tozer, et al. (1999). "Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues." <i>Cancer Research</i> 59(7): 1626-34. ABSTRACT
	C25	Eikesdal, et al. (1999). "The importance of timing in thermochemotherapy with tubulin inhibitors." <i>Eur. J. Cancer</i> 35(4 Supp.): S105. ABSTRACT.
	C26	Koutcher, et al. (1999). "Combretastatin A-4 phosphate depletes tumor energy and enhances the effect of mitomycin C but not radiation in a murine mammary carcinoma." <i>Proc. Am. Assoc. Cancer Res.</i> 40(90 Meet. 6): 0197-016X. ABSTRACT.
	C27	Murata, et al. (1999). "Improving conventional cancer therapy by targeting tumor vasculature." <i>Br. J. Cancer</i> 80(2): 90. ABSTRACT.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C28	Murata, et al. (1999). "Improving anti-cancer therapy by targeting the tumor vasculature with combrestatins." <i>Eur. J. Cancer</i> 35(4): S179. ABSTRACT.
	C29	Siemann, et al. (1999). "Potentiation of chemotherapy by vascular targeting agents." <i>Br. J. Cancer</i> 80(Suppl. 2): 90. ABSTRACT.
	C30	Li, et al. (1998). "Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy." <i>International Journal of Radiation Oncology, Biology, Physics</i> 42(4): 899-903. ABSTRACT.
	C31	Siemann, et al. (1998). "Targeting the tumor vasculature with combretastatin A-4 prodrug enhances the antitumor treatment efficacy of cisplatin." <i>Proc. Am. Assoc. Cancer Res.</i> 39(89): 277-278. ABSTRACT.
	C32	Ohsumi, et al. (1999). "Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins." <i>Anti-Cancer Drug Design</i> 14:539-548.
	C33	Lin, et al. (1989). "Interactions of Tubulin with Potent Natural and Synthetic Analogs of the Antimitotic Agent Combretastatin: a Structure-Activity Study." <i>Molecular Pharmacology</i> 34:200-208.
	C34	Grosios, et al. (2000). "Combination Chemotherapy with Combretastatin A-4 Phosphate and 5-Fluorouracil in an Experimental Murine Colon Adenocarcinoma." <i>AntiCancer Res.</i> 20:229-234
	C35	OxIGENE Annual Report. Annual Meeting of Shareholders (May 26, 2000)
	C36	Jordon, et al. (1998). "Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle." <i>Med. Res. Rev.</i> 18(4):259-96. ABSTRACT.
	C37	Chaplin, et al. (1996). "Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents." <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> 37: A3009. ABSTRACT.
	C38	Chaplin, et al. (1996). "Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents." <i>British Journal of Cancer.</i> 74(Supplement 27): S-86-S88. ABSTRACT.
	C39	Remick (2000). ASCO Poster Presentation, Case Western Univ.
	C40	Galbraith (2001). "Combretastatin A4 Phosphate Reduces Tumor Blood Flow in Animals and Man, Demonstrated by MRI." ASCO ABSTRACT 278.
	C41	Rustin (2001). "Phase 1 Study of Weekly Intravenous Combretastatin A4 Phosphate (CA4P); Pharmacokinetics and Toxicity." ASCO ABSTRACT 392.
	C42	Anderson (2000). "Measurement of Tumour and Normal Tissue (NT) Perfusion by Positron Emission Tomography (PET) in the Evaluation of Antivascular Therapy: Results in the Phase 1 Study of Combretastatin A4 Phosphate (CA4P)." ASCO ABSTRACT 695.
	C43	Nelkin and Bali (2001). "Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma." <i>Oncology Reports</i> 8:157-160.
	C44	Horsman, et al. (2000). "Combretastatin Novel Vascular Targeting Drugs for Improving Anti-Cancer Therapy." <i>Angiogenesis; From the Molecular to Integrative Pharmacology</i> pgs.311-323.
	C45	Griggs, et al. (2001). "Targeting tumour vasculature: the development of combretastatin A4" <i>The Lancet Oncology</i> 2:82-87.
	C46	Landuyt, et al. (2001). "In Vivo Antitumor Effect of Vascular Targeting Combined with Either Ionizing Radiation or Anti-Angiogenesis Treatment." <i>Int. J. Radiation Oncology Biol. Phys.</i> 49(2):443-450.
	C47	Landuyt, et al. (2000). "Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas" <i>European Journal of Cancer</i> 36: 1833-1843.
	C48	Dark, et al. (1997). "Combretastatin A-4, an Agent That Displays Potent and Selective Toxicity toward Tumor Vasculature" <i>Cancer Research</i> 57:1829-1834
	C49	Siemann, et al. (2000). "Targeting tumor blood vessels: an adjuvant strategy for radiation therapy" <i>Radiotherapy and Oncology</i> 57: 5-12.
	C50	Siemann, et al. (2002). "Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities In Solid Tumor Therapy" <i>Int. J. Canc.</i> 99: 1-6.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C51	Pedley, et al. (2001). "Eradication of Colorectal Xenografts by Combined Radiolimmunotherapy and Combretastatin A-4 3-O-Phosphate" <i>Cancer Res.</i> 61: 4716-4722.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 1677737v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Lee, et al.
SERIAL NUMBER : 10/027,186 EXAMINER : Not Yet Assigned
FILING DATE : December 20, 2001 ART UNIT : 1614
FOR : Methods for Modulating Tumor Growth and Metastasis

BOX IDS

Commissioner for Patents
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (4 pages), in duplicate;
3. Copies of Cited References A1-A7, B1-B8 and C1-C51; and
4. Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 18217-505. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elm, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: June 12, 2002

TRA 1678314v1

EV074978465US



POST OFFICE




EV 074978465 US



POST OFFICE
TO ADDRESSEE



EV 074978465 US



Customer Copy
Label 11-F August 2000

Label 11-F August 2000

ORIGIN (POSTAL USE ONLY)		Flat Rate Envelope	
PO ZIP Code 02205	Day of Delivery Next <input type="checkbox"/> Second <input type="checkbox"/>	Postage \$ 30.45	
Date In 6/12/02	Time In 12 Noon <input type="checkbox"/> 3 PM <input type="checkbox"/>	Return Receipt Fee	
Weight 7.33 lbs	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day <input type="checkbox"/>	COD Fee	
Int'l Alpha Country Code	Acceptance Clerk Initials	Insurance Fee	
No Delivery <input type="checkbox"/>	Weekend <input type="checkbox"/> Holiday <input type="checkbox"/>	Total Postage & Fees \$ 30.45	

SEE REVERSE SIDE FOR
SERVICE GUARANTEE AND LIMITS
ON INSURANCE COVERAGE

WAIVER OF SIGNATURE (Domestic Only): Additional merchandise insurance is void if waiver of signature is requested. Unless delivery is made without obtaining signature of addressee or addressee's agent in delivery employee judges that article can be left in secure location and authorizes that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY ☐ Weekend ☐ Holiday ☐ Customer Signature

CUSTOMER USE ONLY
METHOD OF PAYMENT:
Express Mail Corporate Acct. No.

FROM: (PLEASE PRINT) PHONE (617) 542-6000
ELRIFI
IVOR R. EVIN PHD
MINTZ LEVIN
FINANCIAL CTR
BOSTON
MA 02111-2621
18217-505 IRE/BJM/TM

TO: (PLEASE PRINT) PHONE ()
BOX 185
ASSISTANT COMMISSIONER
FOR PATENTS
WASHINGTON
DC 20231-0001


FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com



Serial No. 10/027,186 File No. 18217-505 By: IRE/BJM/TM
Title: Methods for Modulating Tumor Growth and Metastasis
Application of Lee, et al. Date: 12/20/01

The U.S. PTO Mail Room acknowledges receipt of the following on the date stamped hereon:

- ☐ Req. for CPA under 37 CFR 1.53(d)
- ☐ Change of Attorney's Address
- ☐ New Power of Attorney
- ☐ Patent Application
 - ☐ Non-provisional ☐ Provisional
 - Incl. _____ pages, (_____ pgs) Specification,
 - (_____ pgs) Abstract, (_____ pgs) Claims (_____ # claims)
- ☐ Design Patent Application
- ☐ Declaration(s)
- ☐ Drawings _____ sheet(s) (FIGS. _____)
 - ☐ Formal ☐ Informal
- ☐ Verified Statement claiming small entity status
- ☐ Assignment and Cover Sheet
- ☐ Other _____
- ☒ Provisional Application Cover Sheet
- ☒ Inf. Disc. Statement PTO Form 1449
- ☒ References Cited A1-A7, B1-B8, C1-51
- ☐ Copy of Notice to File Missing Parts
- ☐ Amendment/Response
- ☐ Petition for Extension of Time (x2)
- ☐ Issue Fee Transmittal
- ☐ Letter to Official Draftsperson
- ☐ Notice of Appeal
- ☐ Brief (x3)
- ☐ Check for _____ Check # _____
- ☐ Transmittal Letter (x2)
- ☐ Cert. of Mailing under 37 CFR 1.801
- ☐ Express Mail Label No. EV074978465US



DATE MAILED June 12, 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

Page 1 of 5

PATENT NO. : 7,037,906
 APPLICATION NO.: 10/027,186
 ISSUE DATE : 2 May 2006
 INVENTOR(S) : Francis LEE, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

The References Cited field at page 1, field 56, should include the following references:

4,940,726 07/10/90 Pettit, et al.
 4,996,237 02/26/91 Pettit, et al.
 5,409,953 04/25/95 Pettit, et al.
 5,561,122 10/01/96 Pettit
 5,569,786 10/29/96 Pettit, et al.
 5,661,143 08/26/97 D'Amato, et al
 6,342,219 01/29/02 Thorpe, et al.

WO 99/35150 Arizona Board of Regents 07/15/1999
 WO 00/48590 Angiogene Pharmaceuticals Ltd. 08/24/2000
 WO 00/48591 Angiogene Pharmaceuticals Ltd. 08/24/2000
 WO 94/05682 Pelizzoni 03/17/1994
 WO 01/74368 Angiogene Pharmaceuticals Ltd. 10/11/2002
 WO 02/09700 Cancer Research Ventures Ltd. 02/07/2002
 WO 02/34244 Aventis Pharma 05/02/2002
 EP 1 068 870 Ajinomoto Co. Inc. 01/17/2001

Pettit and Rhodes (1998). "Antineoplastic Agents 389. New Syntheses of the combretastatin A-4 prodrug"
 Anti-Cancer Drug Design 13: 183-191.

Petit, et al. (1995). "Antineoplastic Agents 291. Isolation and Synthesis of Combretastatins A-4, A-5 and A-61a"
 J. Med. Chem. 38: 1666-1672.

Crombie, et al. (1979). "Isolation of Cannabispiradienone and Cannabidihydrophenantherene. Biosynthetic
 Relationships Between the spirans and dihydrostilbenes of Thailand Cannabis" Tetrahedron Letts.
 7: 661-664.

Majumder and Joardar. (1984). "Structure of Erianin, a New Bibenzyl Derivative from the Orchid Eria carinata"
 Indian J Chem. 23B: 1040-1042.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Karen E. Flick
 P.O. Box 515
 El Granada, CA 94018-0515

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 5

PATENT NO. : 7,037,906
APPLICATION NO.: 10/027,186
ISSUE DATE : 2 May 2006
INVENTOR(S) : Francis LEE, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Furstner and Nikolakis (1996). "Ethynylation of Aryl Halides by a Modified Suzuki Reaction: Application to the Synthesis of Combretastatin A-4, A-5 and Lunularic Acid" Liebig's Ann. Pgs. 2107-2113.
Remick, et al. (2000). "A Phase I Pharmacokinetic (PK) Study of Single Dose Intravenous (IV) Combretastatin A4 Prodrug (CA4P) in Patients (PTS) With Advanced Cancer" ASCO Presentation. New Orleans May 23 2000
Stevenson, et al. (2000). "Phase I/Pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x5 schedule every 21 days" ACCR San Francisco, CA .
Rustin, et al. (1999). "Combretastatin A4 phosphate (CA4P) selectively targets vasculature in animal and human tumors." Proceedings of the 1999 AACR-NCI-EORT International Conference. Mount Vernon Hospital, Northwood Middlesex UK. Abstract 14.
Galbraith, et al. (1999). "Quantitative analysis of endothelial cell shape change after treatment with combretastatin A4 phosphate." AACR-NCI-EORTC International Conference. Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Northwood, UK. Abstract 399.
J. Randal, et al. (2000). "Antiangiogenesis Drugs Target Specific Cancers, Mechanisms." J National Cancer Institute 92(7): 520-522.
OXIGENE Announces Promising Clinical Results for Lead Tumor Vascular Targeting Agent, Combretastatin A4 Prodrug. Press Release.
OXIGENE Signs Letter of Intent with Bristol-Myers Squibb for the Development and Commercialization of Combretastatin. Press Release (22 November 1999). pages 1-2.
Bristol-Myers Squibb/Oxigene HEALTH-NEWS-Daily (23 November 1999). Press Release.
OXIGENE announces favorable phase I results for angiogenesis inhibitor. Reuters Medical News. (7 October 1999). Press Release.
OXIGENE announces favorable phase I results for angiogenesis inhibitor. Reuters Medical News. (7 October 1999). Press Release.
OXIGENE acquires rights to combretastatin. Reuters Medical News. (13 August 1999). Press Release
Bristol-Myers Squibb and OXIGENE Announce Research and Licensing Agreement for Anti-Tumor Agents. Press Release. Princeton New Jersey (16 December 1999) pgs.1-3.
Eikesdal, et al. (2000). "The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma." Int. J Radiat. Oncol. Biol. Phys. 46(3): 645-652. ABSTRACT

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Karen E. Flick
P.O. Box 515
El Granada, CA 94018-0515

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 4

PATENT NO. : 7,037,906
 APPLICATION NO.: 10/027,186
 ISSUE DATE : 2 May 2006
 INVENTOR(S) : Francis LEE, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Furstner and Nikolakis (1996). "Ethynylation of Aryl Halides by a Modified Suzuki Reaction: Application to the Synthesis of Combretastatin A-4, A-5 and Lunularic Acid" Liebig's Ann. Pgs. 2107-2113.
 Remick, et al. (2000). "A Phase I Pharmacokinetic (PK) Study of Single Dose Intravenous (IV) Combretastatin A4 Prodrug (CA4P) in Patients (PTS) With Advanced Cancer" ASCO Presentation. New Orleans May 23 2000
 Stevenson, et al. (2000). "Phase II Pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an N bolus on a daily x5 schedule every 21 days" ACCR San Francisco, CA .
 Rustin, et al. (1999). "Combretastatin A4 phosphate (CA4P) selectively targets vasculature in animal and human tumors." Proceedings of the 1999 AACR-NCI-EORT International Conference. Mount Vernon Hospital, Northwood Middlesex UK. Abstract 16.
 Galbraith, et al. (1999). "Quantitative analysis of endothelial cell shape change after treatment with combretastatin A4 phosphate." AACR-NCI-EORTC International Conference. Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Northwood, UK. Abstract 399.
 J. Randal, et al. (2000). "Antiangiogenesis Drugs Target Specific Cancers, Mechanisms." J National Cancer Institute 92(7): 520-522.
 OXIGENE Announces Promising Clinical Results for Lead Tumor Vascular Targeting Agent, Combretastatin A4 Prodrug. Press Release.
 OXIGENE Signs Letter of Intent with Bristol-Myers Squibb for the Development and Commercialization of Combretastatin. Press Release (22 November 1999). pages 1-2.
 Bristol-Myers Squibb/Oxigene HEALTH-NEWS-Daily (23 November 1999). Press Release.
 OXIGENE announces favorable phase I results for angiogenesis inhibitor. Reuters Medical News. (7 October 1999). Press Release.
 OXIGENE announces favorable phase I results for angiogenesis inhibitor. Reuters Medical News. (7 October 1999). Press Release.
 OXIGENE acquires rights to combretastatin. Reuters Medical News. (13 August 1999). Press Release
 Bristol-Myers Squibb and OXIGENE Announce Research and Licensing Agreement for Anti-Tumor Agents. Press Release. Princeton New Jersey (16 December 1999) pgs.1-3.
 Eikesdal, et al. (2000). "The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma." Int. J Radiat. Oncol. Biol. Phys. 46(3): 645-652. ABSTRACT

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Karen E. Flick
 P.O. Box 515
 El Granada, CA 94018-0515

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 4 of 5

PATENT NO. : 7,037,906
 APPLICATION NO.: 10/027,186
 ISSUE DATE : 2 May 2006
 INVENTOR(S) : Francis LEE, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Siemann, et al. (1998). "Targeting the tumor vasculature with combretastatin A-4 prodrug enhances the antitumor treatment efficacy of cisplatin." Proc. Am. Assoc. Cancer Res. 39(89): 277-278. ABSTRACT.
 Ohsumi, et al. (1999). "Synthesis and antitumor activities of amino acid prodrugs of aminocombretastatins." Anti-Cancer Drug Design 14:539-548.
 Lin, et al. (1989). "Interactions of Tubulin with Potent Natural and Synthetic Analogs of the Antimitotic Agent Combretastatin: a Structure-Activity Study." Molecular Pharmacology 34:200-208.
 Grosios, et al. (2000). "Combination Chemotherapy with Combretastatin A-4 Phosphate and 5-Fluorouracil in an Experimental Murine Colon Adenocarcinoma." AntiCancer Res. 20:229-234
 OXiGENE Annual Report. Annual Meeting of Shareholders (May 26, 2000)
 Jordon, et al. (1998). "Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle." Med. Res. Rev.18(4):259-96. ABSTRACT.
 Chaplin, et al. (1996). "Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents." Proc. Annu. Meet. Am. Assoc. Cancer Res. 37: A3009. ABSTRACT.
 Chaplin, et al. (1996). "Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents." British Journal of Cancer. 74(Supplement 27): S-86-S88. ABSTRACT.
 Remick (2000). ASCO Poster Presentation, Case Western Univ.
 Galbraith (2001). "Combretastatin A4 Phosphate Reduces Tumor Blood Flow in Animals and Man, Demonstrated by MRI." ASCO ABSTRACT 278.
 Rustin (2001). "Phase 1 Study of Weekly Intravenous Combretastatin A4 Phosphate (CA4P); Pharmacokinetics and Toxicity." ASCO ABSTRACT 392.
 Anderson (2000). "Measurement of Tumour and Normal Tissue (NT) Perfusion by Positron Emission Tomography (PET) in the Evaluation of Antivascular Therapy: Results in the Phase 1 Study of Combretastatin A4 Phosphate (CA4P)." ASCO ABSTRACT 695.
 Nelkin and Ball (2001). "Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma." Oncology Reports 8:157-160.
 Horsman, et al. (2000). "Combretastatin Novel Vascular Targeting Drugs for Improving Anti-Cancer Therapy." Angiogenesis; From the Molecular to Integrative Pharmacology pgs.311-323.
 Griggs, et al. (2001). "Targeting tumour vasculature: the development of combretastatin A4" The Lancet Oncology 2:82-87.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Karen E. Flick
 P.O. Box 515
 El Granada, CA 94018-0515

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 5 of 5

PATENT NO. : 7,037,906
APPLICATION NO.: 10/027,186
ISSUE DATE : 2 May 2006
INVENTOR(S) : Francis LEE, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Landuyt, et al. (2001). "In Vivo Antitumor Effect of Vascular Targeting Combined with Either Ionizing Radiation or Anti-Angiogenesis Treatment." Int. J. Radiation Oncology Biol. Phys. 49(2):443-450.

Landuyt, et al. (2000). "Vascular targeting of solid tumours: a major 'inverse' volume response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas" European Journal of Cancer 36: 1833-1843.

Dark, et al. (1997). "Combretastatin A-4, an Agent That Displays Potent and Selective Toxicity toward Tumor Vasculature" Cancer Research 57:1829-1834

Siemann, et al. (2000). "Targeting tumor blood vessels: an adjuvant strategy for radiation therapy" Radiotherapy and Oncology 57: 5-12.

Siemann, et al. (2002). "Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities In Solid Tumor Therapy" Int. J. Cancer. 99: 1-6.

Pedley, et al. (2001). "Eradication of Colorectal Xenografts by Combined Radioimmunotherapy and Combretastatin A-4 3-O-Phosphate" Cancer Res. 61: 4716-4722.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Karen E. Flick
P.O. Box 515
El Granada, CA 94018-0515

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.